Krystal Biotech, Inc.
KRYS
$143.96
-$2.34-1.60%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 8.91% | -3.24% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 8.91% | -3.24% | |||
| Cost of Revenue | 42.50% | 1.60% | |||
| Gross Profit | 6.88% | -3.52% | |||
| SG&A Expenses | 7.45% | 4.59% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.09% | 4.51% | |||
| Operating Income | 8.65% | -12.57% | |||
| Income Before Tax | 7.29% | -10.31% | |||
| Income Tax Expenses | 7.35% | 151.17% | |||
| Earnings from Continuing Operations | 7.28% | -21.43% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 7.28% | -21.43% | |||
| EBIT | 8.65% | -12.57% | |||
| EBITDA | 8.19% | -12.06% | |||
| EPS Basic | 6.92% | -21.59% | |||
| Normalized Basic EPS | 6.94% | -10.51% | |||
| EPS Diluted | 7.50% | -21.37% | |||
| Normalized Diluted EPS | 7.73% | -10.28% | |||
| Average Basic Shares Outstanding | 0.33% | 0.21% | |||
| Average Diluted Shares Outstanding | -0.41% | -0.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||